Case Report: A Promising Treatment Strategy for Noninfectious Uveitis

@article{Liu2022CaseRA,
  title={Case Report: A Promising Treatment Strategy for Noninfectious Uveitis},
  author={Xiaobing Liu and Lu-Shi Tang and Jing-wen Chen and Changsong Lin and Qiu-hong Liu and Qiang Xu},
  journal={Frontiers in Pharmacology},
  year={2022},
  volume={12}
}
Background: Uveitis refers to inflammation in the uvea, retina, retinal blood vessels, and vitreous, which can lead to irreversible eye damage and permanent vision loss. Glucocorticoid drugs are the first-line treatment, but side effects, such as obesity and hyperglycemia, can occur. Therefore, biologics have become a new treatment choice. Case Presentation: A 18-year-old girl developed eye pain and was diagnosed with binocular uveitis. Prednisone 50 mg was administered once a day, and the… 
2 Citations

Figures and Tables from this paper

Treatment Options in Pediatric Behçet’s Disease

A growing interest has developed around anti-tumor necrosis factor agents that have often proven to be effective in severe cases, especially in those with a gastrointestinal and ocular involvement.

Multiple drugs

  • Reactions Weekly
  • 2022

References

SHOWING 1-10 OF 21 REFERENCES

Treatment of ocular inflammatory conditions with loteprednol etabonate

Loteprednol etabonate appears to have an improved safety profile compared with ketone corticosteroids, and may be more suitable for the treatment for ocular inflammatory conditions in which long-term therapy is necessary, but further comparative safety studies are needed.

Understanding uveitis: The impact of research on visual outcomes

JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis

JAK inhibitors may provide a new valuable treatment option in the therapeutic armamentarium for patients affected with JIA-associated uveitis, particularly in those refractory cases that are not adequately responding to conventional or biologic DMARDs.

Uveitis- a rare disease often associated with systemic diseases and infections- a systematic review of 2619 patients

Ophthalmologists, rheumatologists, infectiologists, neurologists and general practitioners should be familiar with the differential diagnosis of uveitis and a better interdisciplinary approach could help in tailoring of the work-up, earlier diagnosis of co-existing diseases and management of Uveitis patients.

Classification of Uveitis - Current Guidelines

The use of classification criteria, supported by standardisation guidelines, is very important for disorders that have a multitude of associated aetiologies. At least 150 disorders are known to be

Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors

In this trial involving patients with active psoriatic arthritis who had had an inadequate response to TNF inhibitors, tofacitinib was more effective than placebo over 3 months in reducing disease activity.

Tofacitinib inhibits the development of experimental autoimmune uveitis and reduces the proportions of Th1 but not of Th17 cells

Treatment with tofacitinib inhibited the development of EAU, reduced the production of IFN-γ, but had essentially no effect on theproduction of IL-17 and its transcription factor, RORγt.

TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1

The findings suggest that TH1 cells may mitigate uveitis by antagonizing the TH17 phenotype through the IFN-γ–mediated induction of IL-27 in target tissue, and suggests that antagonism of TH17 by IFn-γ and/or IL- 27 could be used for the treatment of chronic inflammation.